



1642
8

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/001,469	
	Filing Date	October 31, 2001	
	First Named Inventor	Aya JAKOBOVITS et al.	
	Group Art Unit	1642	
	Examiner Name	To Be Assigned	
Total Number Of Pages In This Submission	6	Attorney Docket No.	511582002420

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement; PTO form 1449	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
Firm or Individual Name	Kawai Lau Registration No. 44,461
Signature	
Date	March 27 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on March 27, 2002.
 Garee A. Hanley

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

RECEIVED
APR 10 2002
TECH CENTER 1600/2900



PATENT
Docket No. 511582002420

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on March 27, 2002.

Garee A. Haney
Garee A. Haney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Aya JAKOBOVITS et al.

Serial No.: 10/001,469

Filing Date: October 31, 2001

For: NUCLEIC ACID AND
CORRESPONDING PROTEIN
ENTITLED 101P3A11 USEFUL IN
TREATMENT AND DETECTION OF
CANCER

Examiner: To Be Assigned

Group Art Unit: 1642

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/680,728, filed October 5, 2000, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d)

RECEIVED
APR 10 2002
TECH CENTER 1600/2900

and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **511582002420**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 27, 2002

Respectfully submitted,

By: 

Kawai Lau
Registration No. 44,461

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5178
Facsimile: (858) 720-5125

Form PTO-1449

Docket Number 511582002420

Application Number 10/001,469

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant

Aya JAKOBOVITS et al.

Filing Date October 31, 2001

Group Art Unit 1642

Mailing Date March 27, 2002

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	12/1996	WO 96/39435	WIPO			
	2.	02/1999	WO 99/06550	WIPO			
	3.	01/2000	WO 00/04149	WIPO			
	4.	04/2000	WO 00/20590	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	5.	Alberts et al., Molecular Biology of the Cell, 3rd Edition (1994) p.465
	6.	Bepler et al., Genomics (1999) 55(2):164-175
	7.	Burgess et al., Journal of Cell Biology (1990) 11:2129-2138
	8.	EMBL Sequence Accession No. A06681.Gcg_Geneseq_D, June 13, 2000 (first entry)
	9.	EMBL Sequence Accession No. AF101565, January 29, 1999, November 8, 2000
	10.	Fu et al., EMBO Journal (1996) 15:4392-4401
	11.	Gillies et al., Human Antibodies and Hybridomas (1990) 1(1):47-54
	12.	Harrison, Immunol Series 49:411-464
	13.	Hubert et al., Proc. Natl. Acad. Sci. USA (1999) 96(25):14523-14528
	14.	Jansen, Pediatric Res. (1995) 37(6):681-686
	15.	Klein et al., Nat. Med. (1997) 3:402
	16.	Lazar et al., Molecular and Cell Biology (1988) 8:1247-1252
	17.	Maniatis et al. (Eds.), Mol. Cloning (1989) Cold Spring Harbor Laboratory, Cold Spring Harbor, p.17.31

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 511582002420

Application Number 10/001,469

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

Applicant

Aya JAKOBOVITS et al.

Filing Date October 31, 2001

Group Art Unit 1642

Mailing Date March 21, 2002

APR 09 2002

(Use several sheets if necessary)

- | | |
|-----|--|
| 18. | McLean and Hill, Eur. J. of Cancer (1993) 29A:2243-2248 |
| 19. | MPSRCH search report, pp. 2-5 |
| 20. | NAGENESEQ, EMBL Sequence Accession No. X40518, June 18, 1999 (first entry) |
| 21. | Pinto et al., Clin. Cancer Res. (1996) 2(9):1445-1451 |
| 22. | Reiter et al., Proc. Natl. Acad. Sci. USA (1998) 95:1735 |
| 23. | Shantz and Pegg, Int. J. of Biochem. and Cell Biol. (1999) 31:107-122 |
| 24. | Sjogren, Immunotechnology (1997) 3(3):161-172 |
| 25. | Su et al., Proc. Natl. Acad. Sci. USA (1996) 93:7252 |
| 26. | Tao et al., The Journal of Immunology (1989) 143(8):2595-2601 |

TECH CENTER 1600/2900

APR 10 2002

RECEIVED

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.